Neutralization groups1 | HuMAb | Percent neutralization (mean ± SD) at different HuMAb doses | ||
---|---|---|---|---|
10 μg/ml | 1.25 μg/ml | 0.156 μg/ml | ||
High | 5C12 | 97 ± 1.7a | 89 ± 4.1a | 73 ± 5.1a |
3E9 | 94 ± 3.3ab | 80 ± 6.5ab | 52 ± 5.3ab | |
2F10 | 89 ± 4.6b | 71 ± 7.6b | 50 ± 4.2b | |
Medium | 7C4 | 69 ± 6.5c | 52 ± 6.2c | 38 ± 4.1c |
6D8 | 68 ± 9.6c | 48 ± 8.5c | 38 ± 3.2c | |
9H9 | 65 ± 10.6c | 48 ± 7.4c | 29 ± 5.9cd | |
6H7 | 64 ± 7.1c | 46 ± 6.5c | 22 ± 4.5d | |
14C12 | 63 ± 6.8c | 39 ± 7.4cd | 29 ± 8.8cd | |
5E12 | 59 ± 9.0cd | 36 ± 6.4cd | 17 ± 4.6de | |
6B7 | 57 ± 6.2cd | 37 ± 5.5cd | 23 ± 3.6d | |
6H5 | 57 ± 5.9cd | 39 ± 3.5cd | 25 ± 3.9d | |
6C3 | 50 ± 7.1de | 37 ± 5.1cd | 16 ± 3.6de | |
1G1 | 46 ± 7.3de | 27 ± 7.5d | 15 ± 1.9de | |
Low | 4H10 | 40 ± 8.5ef | 13 ± 5.3e | 10 ± 5.3e |
5F2 | 35 ± 4.7f | 13 ± 5.5e | 1 ± 0.7f | |
6E6 | 34 ± 5.6f | 25 ± 6.1d | 9 ± 4.6e | |
3A2 | 31 ± 8.1fg | 15 ± 8.1e | 14 ± 9.1de | |
7F2 | 25 ± 4.7g | 14 ± 7.8e | 7 ± 5.1e | |
1G12 | 15 ± 4.7h | 11 ± 5.9e | 10 ± 5.5e | |
Placebo control | IgG1κ | 5 ± 3.8h | 5 ± 1.7e | 2 ± 1.5f |